Florence Binlich
Servier (France)(FR)Institut des Hautes Études Scientifiques(FR)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Peptidase Inhibition and Analysis, Acute Myeloid Leukemia Research, CAR-T cell therapy research
Most-Cited Works
- → Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial(2014)783 cited
- → Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies(2020)351 cited
- → Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial(2016)145 cited
- → Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment(2015)131 cited
- → UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial(2022)124 cited
- → A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer(2006)45 cited
- → Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents(2020)43 cited
- → From single-arm studies to externally controlled studies. Methodological considerations and guidelines(2019)41 cited
- → Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma(2015)28 cited
- → Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia(2017)28 cited